| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
191,170,000 |
| Market
Cap: |
13.01(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.14 - $79.91 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipeline are: Acoramidis/AG10/BBP-265, a small molecule transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Infigratinib/BBP-831, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer for the treatment of congenital adrenal hyperplasia; and Encaleret, a small molecule antagonist of the calcium sensing receptor for the treatment of Autosomal Dominant Hypocalcemia Type 1.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
364,184 |
1,074,961 |
17,636,375 |
27,240,995 |
| Total Sell Value |
$25,709,029 |
$67,025,883 |
$666,734,358 |
$949,087,410 |
| Total People Sold |
5 |
8 |
13 |
13 |
| Total Sell Transactions |
11 |
25 |
52 |
65 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kumar Neil |
Chief Executive Officer |
• • – |
2026-01-09 |
4 |
AS |
$75.61 |
$3,084,313 |
I/I |
(40,000) |
4,518,447 |
|
0% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2026-01-08 |
4 |
AS |
$73.64 |
$2,958,855 |
I/I |
(40,000) |
4,538,447 |
|
5% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-12-15 |
4 |
AS |
$74.60 |
$2,239,902 |
D/D |
(30,011) |
228,776 |
|
4% |
|
| Apuli Maricel |
Chief Accounting Officer |
• – – |
2025-12-12 |
4 |
D |
$75.15 |
$150,525 |
D/D |
(2,003) |
128,294 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-12-12 |
4 |
D |
$75.15 |
$2,326,945 |
D/D |
(30,964) |
258,787 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-12-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,975 |
289,751 |
|
- |
|
| Trimarchi Thomas |
President and CFO |
• – – |
2025-12-12 |
4 |
D |
$75.15 |
$1,039,024 |
D/D |
(13,826) |
369,004 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-12-05 |
4 |
AS |
$73.04 |
$2,932,563 |
I/I |
(40,000) |
4,558,447 |
|
5% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-12-04 |
4 |
AS |
$73.16 |
$2,975,913 |
I/I |
(40,000) |
4,578,447 |
|
3% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-11-20 |
4 |
AS |
$64.97 |
$1,722,224 |
D/D |
(26,156) |
228,776 |
|
20% |
|
| Lo Andrew |
Director |
– • – |
2025-11-18 |
4 |
S |
$65.23 |
$3,613,069 |
I/I |
(55,000) |
50,583 |
|
3% |
|
| Scott Randal W |
Director |
– • – |
2025-11-17 |
4 |
AS |
$66.25 |
$666,465 |
D/D |
(10,000) |
11,589 |
|
16% |
|
| Scott Randal W |
Director |
– • – |
2025-11-17 |
4 |
OE |
$16.75 |
$167,500 |
D/D |
10,000 |
21,589 |
|
- |
|
| Lo Andrew |
Director |
– • – |
2025-11-17 |
4 |
S |
$66.63 |
$2,706,593 |
D/D |
(40,599) |
14,089 |
|
5% |
|
| Trimarchi Thomas |
President and CFO |
• – – |
2025-11-17 |
4 |
AS |
$66.19 |
$1,125,404 |
D/D |
(16,934) |
382,830 |
|
16% |
|
| Apuli Maricel |
Chief Accounting Officer |
• – – |
2025-11-16 |
4 |
D |
$66.39 |
$317,411 |
D/D |
(4,781) |
132,297 |
|
- |
|
| Trimarchi Thomas |
President and CFO |
• – – |
2025-11-16 |
4 |
D |
$66.39 |
$1,415,236 |
D/D |
(21,317) |
399,764 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-11-16 |
4 |
D |
$66.39 |
$2,181,243 |
D/D |
(32,855) |
254,932 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-11-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
64,697 |
287,787 |
|
- |
|
| Valantine Hannah |
Director |
– • – |
2025-11-12 |
4 |
S |
$66.07 |
$1,683,728 |
D/D |
(25,484) |
7,465 |
|
4% |
|
| Valantine Hannah |
Director |
– • – |
2025-11-12 |
4 |
OE |
$48.45 |
$1,234,700 |
D/D |
25,484 |
32,949 |
|
- |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-11-07 |
4 |
AS |
$61.13 |
$2,456,994 |
I/I |
(40,000) |
795,686 |
|
25% |
|
| Kumar Neil |
Chief Executive Officer |
• • – |
2025-11-06 |
4 |
AS |
$62.91 |
$2,526,117 |
I/I |
(40,000) |
815,686 |
|
23% |
|
| Daniels Ronald J |
Director |
– • – |
2025-11-06 |
4 |
S |
$63.72 |
$3,888,999 |
D/D |
(61,031) |
16,991 |
|
-2% |
|
| Daniels Ronald J |
Director |
– • – |
2025-11-06 |
4 |
OE |
$34.65 |
$2,114,724 |
D/D |
61,031 |
78,022 |
|
- |
|
427 Records found
|
|
Page 1 of 18 |
|
|
4.32 (6.78%) 
